OR WAIT null SECS
May 23, 2018
Allergan will buy a potential depression treatment from Aptinyx.
The new company will develop proprietary RNA-based therapeutics and will provide broad lentiviral development and manufacturing expertise and support.
May 22, 2018
The company has leased and purchased facilities in the United States and Europe to expand its cell therapy pipeline.
May 21, 2018
The agency approved Amgen and Novartis’ Aimovig (erenumab-aooe), the first FDA-approved preventive treatment for migraine in adults.
The acquisition of AurKa Pharma will help strength Eli Lilly’s oncology pipeline.
May 16, 2018
The agency has approved Retacrit (epoetin alfa-epbx) by Pfizer’s Hospira, which is a biosimilar to Amgen’s anemia drug, Epogen/Procrit (epoetin alfa).
The acquisition is expected to strengthen Novartis’ gene therapy pipeline.
May 15, 2018
Eli Lilly will acquire ARMO BioSciences to strengthen Lilly's immuno-oncology program.
May 14, 2018
Barriers impede biosimilar market entry into the United States despite the Biologics Price Competition and Innovation Act.
May 09, 2018
The companies expanded their partnership to develop and commercialize messenger RNA (mRNA) cancer vaccines to include shared-antigen mRNA cancer vaccines such as mRNA-5671.